This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Robert J. Joynt, MD, PhD

JAMA. 1993;270(2):228-230.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The changes in the practice of neurology have been dramatic in the past decade. Physicians graduating over 20 years ago recollect a specialty with great intellectual challenges but with few therapeutic opportunities. Now therapy is advancing in many areas, and major trials are providing information about treatment efficacy, failures, side effects, and complications. Therapies are based on the fundamental knowledge of the disease processes learned through the use of new research techniques.

There here is now some promise of altering the course of multiple sclerosis by vaccine therapy, intravenous immunoglobulin, or use of interferon. The vaccine is made up of immunogenic fragments of myelin basic protein. Experimental studies indicate that this vaccination will largely prevent the induction of allergic encephalomyelitis, a model for multiple sclerosis, in laboratory animals.¹ Intravenous immunoglobulin has been used for a number of autoimmune disorders, including chronic inflammatory demyelinating neuropathy, myasthenia gravis, and inflammatory myopathies. . . . [Full Text PDF of this Article]

Author Affiliations
University of Rochester (NY)

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?